Similar to primary resistance, defects in antigen presentation and IFN-γ signaling, neoantigen depletion, and anergic T cells in tumor all contribute to acquired resistance to ICBs therapies.593 To overcome the resistance to ICBs, substantial efforts have been made on combinatorial approaches to broaden the responders and lower the toxicities. This evidence concerns the gene IFNG and neoplasm.